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ABSTRACT 
The use of animal-origin components and media in the commercial 
production of clostridial antigens for veterinary vaccine manufacture constitutes an 
unnecessary and excessive risk to food safety and health.  For over 70 years, 
bacterial strains of the genus Clostridium have been used in the manufacture of 
veterinary and human vaccines to prevent infection and death.  The vast majority of 
these products are made using animal-based components, including brain, heart and 
liver infusions, meat peptones and casein digests.  Over the last twenty years, the 
threat of Transmissible Spongiform Encephalopathy (TSE) and adventitious 
oncogenic viral transmission has generated a significant concern about the safety and 
reliability of animal-based products.  While many animal-free options have been 
developed in recent years, few manufacturers have adapted vaccine production 
processes to incorporate such media, primarily due to monetary costs, regulatory 
restrictions, and corporate inertia.   Several manufacturers have made progress on the 
transition from animal-based to plant-based medias to reduce the TSE risk, but the 
majority of clostridial vaccines manufactured worldwide are still in animal-based 
media.  While the regulatory agencies responsible for overseeing the human 
pharmaceutical and vaccine manufacturers have been aggressive in requiring the 
removal of animal-based components from the products, the animal health regulatory 
bodies have been slower to follow suit.  A rapid and aggressive shift in policy is 
needed to provide the necessary changes to eliminate the risk of TSE from the 
livestock vaccine industry.
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Chapter 1 – THE CLOSTRIDIA 
 
Ancient Threats in a Modern World 
 
Tetanus, gangrene, and botulism.  Throughout history, the diseases caused by 
bacteria in the genus Clostridium have killed, disabled and disfigured countless millions 
of people.  Equally as damaging has been the loss of livestock upon which our diets 
depend.  It has only been in the last century with the advent of vaccines and modern 
medicine that the scourge of these terrifying threats has diminished to near 
imperceptible memories.  Yet underlying the seemingly miraculous cures brought about 
by such vaccines and treatments lie hidden dangers that only in the last few decades 
have been recognized.   
The cause of this new threat is the way the vaccines are manufactured, including 
the media and components used to make them.  For well over 100 years, the most 
common basal component in clostridial growth media has been bovine sourced meat 
and organs.  For the clostridia, there are few more effective substrates to live and grow 
in than an oxygen-deprived, sulfide-laced stew of boiled beef muscle, brains, livers and 
hearts.  The bacteria grow fast and efficiently, and pump out deadly toxins in large 
quantities in this enriched medium.  In the contained setting of a modern veterinary 
vaccine manufacturing facility, these toxins and antigenic cellular components are 
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concentrated, purified, refined and formulated into life-saving vaccines and medicines 
that have saved millions of lives and billions of dollars worldwide. 
 The first recorded instances of clostridial disease date from the Greek physician 
Hippocrates around 400 B.C., when he described a disease that has been diagnosed as 
gas gangrene, caused by the bacterium Clostridium histolyticum.  Tetanus was first 
definitively described in Sir Charles Bell’s Essays on the Anatomy and Philosophy of 
Expression in 1824 (Bell, 1824).  However, recognition of the disease states did not 
provide a direct diagnosis of the causative organisms.   It wasn’t until the 1860s when 
Louis Pasteur described a microbe that was capable of growing without air, which he 
dubbed Vibrio butyrique, that the first identified member of the genus Clostridium was 
recognized (Bahl & Dèurre, 2001).  He also coined the term “anaerobic” to describe life 
that could survive without free oxygen. 
 The first clostridia to be isolated in pure culture were C. tetani and C. butyricum 
in the late 1890s, followed by isolation of C. perfringens a few years later.  Over the 
course of the following century, over one hundred different clostridial species have 
been isolated and described, many of which have been put to use in the biomedical and 
biotechnological industries.  However, it has always been the disease-causing species 
that have received the greatest attention in the public eye.  The most potent toxins in the 
world are made by clostridia – tetanus and botulinum toxins.  With a median lethal dose 
(LD50) of less than 1 ng/kg, infection with only a few spores of either of these bacteria is 
often enough to cause death to unprotected animals.  And while these are the two most 
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potent toxins in the clostridial genus, they are far from the only ones.  The enteric and 
histotoxic strains generate as much damage and death from diseases such as gangrene, 
blackleg, enterotoxemia, and others (Smith, 1968).   
 Farm fields provide an inviting and rich environment for clostridial bacteria to 
live in.  There are abundant food sources, from the feed and animal waste that is spilled 
liberally on the ground, to the opportunistic infections that can be inflicted upon the 
livestock roaming the farm.  If times get difficult or threatening to the bacteria, they 
form hardy spores, their own protective survival mechanism.  Clostridial spores are 
extremely resistant to harsh treatments, such as heat, chemicals and radiation, so they 
will survive exposures and cleaning regimes that remove vegetative bacterial cells.  
When more compatible circumstances arrive, the spore can rapidly germinate into a 
replicating vegetative cell which can cause disease and loss of livestock. (Bahl & 
Dèurre, 2001) 
 
The Diseases They Cause 
 
A frightening list of debilitating, disfiguring and deadly diseases are caused by the 
clostridia.  In humans, the most well known are the neurotoxigenic pathogens, C. 
botulinum and C. tetani.  Although these are historically the most well known, some 
lesser known cousins are beginning to make headlines around the world.  Clostridium 
difficile has become one of the most dangerous and common nosocomial infections 
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worldwide, affecting 13 people per 1000 hospitalizations in the United States alone 
(Goldstein, 2008).  The toxins produced by clostridial species are some of the most 
lethal known, with the neurotoxins from botulinum and tetanus having a human LD50 of 
less than 1 ng/kg (Gill, 1982). 
 The threat of clostridial infection in farmed animals is even greater.  Not only 
are the neurotoxic organisms a serious problem, but wound infections, hepatic 
infections and kidney diseases all can create a tremendous economic loss.  An animal 
infected with any one of these diseases is almost always considered a total loss to the 
producer, with mortality rates of well over 90-95% for nearly all clostridial infections.  
Because clostridia can survive as spores in exposed soils, stagnant waters and manure, 
the potential risk of contamination of herd animals is very high.   
 Skin wounds can be infected with a number of different species, such as C. 
novyi, C. perfringens or C. septicum.  These gangrenous infections, if untreated, will 
rapidly spread into the musculature of the animal, causing extreme tissue necrosis and 
eventually death.  Other diseases such as redwater, enterotoxicemia, blackleg and 
tetanus maim and kill many more livestock. 
The ubiquitous distribution of clostridial strains in the environment gives rise to 
a very impressive list of livestock diseases, affecting nearly all species.  Cattle, horses, 
sheep, poultry and swine all are affected by clostridial diseases, with the most prevalent 
arising in cattle and sheep (Table 1).    
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 It is nearly impossible to avoid the clostridia when raising agricultural livestock.  
Thus, the only way to prevent significant losses to these diseases is through aggressive 
and prophylactic vaccination.  Fortunately, the vaccines that have been developed are 
extremely efficacious, readily available and very inexpensive. 
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Table 1: Clostridial Infectious Diseases of Livestock (Sippel, 1972) 
 
Disease Species 
affected 
Clostridial 
Species 
Predisposing 
causes 
Features and comments 
Black disease 
(infectious 
necrotic 
hepatitis) 
Sheep 
mainly. 
Cattle 
rarely. 
Cl. Novyii 
Damage to liver by 
young migrating liver 
fluke 
Sudden death, particularly in sheep. Plug 
of yellowish dead tissue in the liver usually 
on the surface but occasionally deeply 
embedded, with signs of liver fluke 
damage. Rapid decomposition of the 
carcass. 
Blackleg Cattle, 
sheep Cl. Chauvoei 
Damage to muscles, 
such as bruising 
following yarding. In 
sheep blackleg tends 
to follow injury, such 
as at vaccination, 
shearing, castration  
Sudden death. Affected animals are 
usually in good condition. May be swelling 
of a leg, the leg may crackle when touched. 
Rapid decomposition and bloating of the 
carcass. The carcass should be disposed 
of to prevent infection of other animals. 
Necrotic enteritis Cattle, poultry 
C. 
perfringens 
type C 
 Unknown at present Bloody diarrhea, lethargy, dehydration.  Death in over 95% of cases 
Redwater 
Disease  
(Bacillary 
Hemoglobinuria) 
Cattle C. hemolyticum 
Damage from liver 
flukes or other causes 
Death is extremely rapid, occurring in 2-3 
hours in young animals, and up to 24 hours 
in older animals, with convulsions prior to 
death. Rapid carcass decomposition gives 
rise to 'pulpy kidneys'. Usually seen as 
outbreaks in sheep 
Malignant 
oedema and 
Gas gangrene 
Sheep 
mainly, also 
cattle and 
goats. 
Cl. Septicum, 
Cl. 
Perfringens 
(type A) 
Deep wounds such 
as dog bites, crow 
attacks and lambing 
injuries. 
Soft swelling followed by a discharge from 
the wound. Death usually occurs after 1-2 
days. Treatment can be attempted through 
the use of antibiotics and cleaning of the 
wound. 
Enterotoxaemia 
(pulpy kidney) 
Sheep, 
cattle and 
goats, 
particularly 
young 
animals 
Cl. 
Perfringens 
(type C/D), 
Cl. Sordellii, 
High levels of starchy 
food in the diet and 
slowing of gut 
movement. 
Death is extremely rapid, occurring in 2-3 
hours in young animals, and up to 24 hours 
in older animals, with convulsions prior to 
death. Rapid carcass decomposition gives 
rise to 'pulpy kidneys'. Usually seen as 
outbreaks in sheep, and the death of just a 
couple of animals in other species. 
Tetanus 
(lockjaw) 
Horses and 
pigs most 
susceptible. 
Cattle, 
sheep and 
goats 
Cl. Tetani 
In sheep, use of 
rubber rings for 
marking; dog bites 
and shearing wounds. 
Signs appear 3-10 days after injury in 
lambs, and longer in other animals. Clinical 
signs include general body stiffness and 
muscular spasms, sensitivity to sound and 
movement, third eyelid protrusion, and 
restricted jaw movement. Most cases die 
within 3-4 days 
In horses, nail pricks 
in hoof. In cattle after 
calving. In pigs after 
castration. Any deep 
penetrating wounds. 
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A New Threat to the Food Supply 
 
 By vaccinating livestock against the most common clostridial diseases, farmers 
worldwide have the ability to stem the loss of profit nearly 100% for a very small 
financial cost.  But this small cost comes with the potential for a much greater risk in 
the future.  In 1986, the first known outbreak of a transmissible form of Bovine 
Spongiform Encephalopathy (BSE) occurred.  The number of infected cattle increased 
for nearly a decade, with no clear medical explanation of how the disease was caused or 
transmitted.  Finally identified as being caused by a prion, the infections were slowly 
contained by massive culling and quarantine efforts that devastated the British cattle 
industry.  Although prion-related diseases have been known to affect humans, either 
through heredity (Creutzfelt-Jacob disease) or cannibalism (Kuru), there was no 
indication that the species barrier between humans and livestock had ever been broken.  
In 1996, a new and frightening development occurred, variant Creutzfeldt-Jakob disease 
(vCJD).  The species barrier into humans had been crossed.  Prions from sheep and 
cattle were shown to cause the disease in humans, meaning that long-term exposure to 
diseased animal products could also infect people.   
 One of the greatest concerns with identifying and tracking prion-based 
infections and the spread of disease through a herd is the lack of any test for the 
presence of prions short of sacrificing the animal.  The only currently accepted and 
definitive test for a TSE disease is a brain necropsy to identify lesions and plaques in 
 8 
the brain.  Although several in vitro test methodologies have been investigated in the 
last 10 years, none have yet proven reliable or accurate enough for any commercial use.  
(Brown, 2005; Supattapone, Geoghegan, & Rees, 2006) 
 While many raw materials suppliers began reducing and/or eliminating animal 
based components from their product lines for human vaccine preparation, there was 
less pressure on the veterinary vaccine industry to make a similar change.  The financial 
and regulatory costs were deemed too great, and without focused government pressure 
there was little incentive to force a switch. 
 
The Cost of Combating the Clostridial Threat 
  
Modern vaccine preparation methods not only refine and concentrate the clostridial 
antigens, but they also have the potential to concentrate other very dangerous 
components that come from the meats and organs that form the media.  Prions and host-
animal antigenic proteins are all retained in the final product.  These unwanted 
contaminants can cause problems ranging from painful localized reactions at the 
injection site, a threat to the health of all animals who receive one or more of these 
vaccines, to an infection risk to every person who consumes the vaccinated animal.   
 It has been estimated that the risk of contracting a prion-based disease from 
tetanus vaccination is less than 1 in 5 billion injections (Prusiner, 2004).  This is a very 
small risk, translating to one potential infection in 50 years of vaccination.  
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Unfortunately, similar risk-assessment is not available for the veterinary vaccinations, 
but a review of the numbers shows the potential risks can rise to be significant.  There 
are over 96 million head of cattle in the United States, and more than 91% are 
immunized against clostridial diseases (USDA-APHIS, 2008a).  These vaccinations are 
most often given as a multiplex dose, with a single inoculation containing fractions to 
protect against up to seven different clostridial strains, and often requiring multiple 
injections over the lifetime of the animal to confer immunity.   
 Without vaccination, an animal that contracts a clostridial disease will almost 
certainly die.  Current clostridial vaccines are inexpensive for the consumer to purchase, 
which restricts the manufacturer’s return on investment to only a fraction of a cent per 
dose.  In 2007, the cost to vaccinate a 100-head herd of cattle with a 7-way clostridial 
vaccine cost less than $25.00 (USDA-APHIS, 2008a).  While such a small cost to the 
farm is considered as a great benefit, the effect on the manufacturer of the vaccine is the 
opposite because of the small fraction of profit that is made on each dose.   
 That slim profit margin for the producer means that there is little direct financial 
incentive to innovate and upgrade a standard process that effectively and cheaply 
generates the product.  Government regulations, which are necessary to ensure the 
safety, stability and consistency of the vaccines, add to this pressure to resist change.  It 
has been estimated that the costs involved in making a radical media change could be 
greater than one million dollars per antigen, per vaccine presentation.  This is because 
of the testing, evaluation and regulatory hurdles that must be overcome.  Although some 
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of this cost could be passed on to the consumer, not all of it would be and the remainder 
would have to be absorbed wholesale by the manufacturer.  With most vaccine 
manufacturers producing between five and seven separate strains and combining them 
into dozens of multivalent vaccine presentations, the financial pressure to not change is 
tremendous. 
 Although there hasn’t been a major shift away from meat-based media to date, 
there is a growing sentiment both in the industry and within the government regulatory 
commissions to change.  Pressure to change to animal-free media and components is 
growing, and in many areas of the world there are increasingly strict regulations and/or 
bans on the use of sera and animal products in the manufacture of new vaccines and 
products.  It is only a matter of time before these restrictions and requirements are 
extended to established products in the United States, which will result in a need for a 
viable alternative media to replace the firmly entrenched processes now used. 
 11 
Chapter 2 – CLOSTRIDIAL VACCINES 
 
Current Clostridial Vaccine Manufacturers 
 
There are only six licensed veterinary clostridial vaccine manufacturers in the 
United States (Table 2).  Unlike most of them, United Vaccines produces only a single 
clostridial bacterial vaccine for protection against C. botulinum intoxication.   The rest 
produce numerous vaccines in various formulations with up to seven separate clostridial 
strains in a single presentation.  With so few makers of these critical veterinary 
vaccines, it is worrisome that there has been so little effort or regulatory pressure to 
move the production to animal-free components. 
 Many of these manufacturers have sibling companies that produce human 
vaccines and biological products.  The FDA has been far more stringent and forceful in 
the push towards an animal-free pharmaceutical mentality, leaving the veterinary sector 
lagging far behind in the safety and modernity of their processes.  This gap is far 
smaller in the European Union regulated nations, where both human and veterinary 
biologics are controlled by a single agency.  Many of the veterinary manufacturers 
either sell products or have facilities located in those European countries, so those 
corporations are more proactive in making an effort to change their processes currently.
 Two manufacturers have licensed clostridal products currently being made with 
animal-free media, Intervet and Pfizer.  However, even in those two cases not  
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TABLE 2: USDA-Licensed Veterinary Clostridial Vaccine Manufacturers 
 (USDA-APHIS, 2008b) 
Company Location Clostridium species produced 
# of 
vaccines 
Current 
Formulation1 
Strains in 
Highest 
Combination 
Boehringer 
Ingelheim 
Vetmedica 
St. Joseph, 
MO 
Chauvoei, Septicum, 
Haemolyticum, Novyi, 
Sordellii, Perfringens 
Types C & D, Tetanus 
Toxoid 
11 CMB, MM 7 
Colorado Serum 
Company Denver, CO 
Chauvoei, Septicum, 
Novyi, Sordellii, 
Perfringens Types C & D 
19 CMB, MM 7 
Intervet, Inc.2 Millsboro, DE 
Chauvoei, Septicum, 
Haemolyticum, Novyi, 
Sordellii, Perfringens 
Types C & D 
20 CMB, MM, AF 7 
Novartis Animal 
Health US, Inc. 
Larchwood, 
IA 
Chauvoei, Septicum, 
Novyi, Sordellii, 
Perfringens Types A, C 
& D 
13 CMB, MM 7 
Pfizer Inc. Lincoln, NE 
Chauvoei, Septicum, 
Haemolyticum, Novyi, 
Sordellii, Perfringens 
Types C & D 
8 CMB, MM, AF 7 
Schering-Plough 
Animal Health 
Corp.2 
Omaha, NE 
Chauvoei, Septicum, 
Haemolyticum, Novyi, 
Sordellii, Perfringens 
Types A, C & D 
13 CMB, MM 7 
United Vaccines, 
Inc. Madison, WI 
Botulinum Type C 
Bacterin 7 CMB, MM 1 
1
 CMB = chopped meat broth, MM = Modified Mueller, AF = Animal-Free  
2Although Schering-Plough acquired Intervet in 2007, both product lines are still produced 
separately. 
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all of the clostridial antigens made by the companies use animal-free media.  The 
majority of products are still produced in either chopped meat broth or Modified-
Mueller media, meaning that even the two companies leading the way in the switch 
to animal-free clostridial products are still far from transitioning their entire 
portfolios over.   
 
Primordial Ooze and Other Growth Media  
 
Most veterinary clostridial vaccines are made using one of only a few choices 
in media preparation (Table 3), either a chopped-meat broth (CMB) or a peptone-
based complex media (modified Muller) (Feeney, Mueller, & Miller, 1943; Mueller 
& Miller, 1942) (Latham et al., 1962).  While most manufacturers have adapted these 
recipes in recent decades to further optimize the antigenicity of their particular strain 
of organism, only a small percentage have succeeded in shifting any of their 
clostridial vaccines to non-animal based media.  This reliance on large quantities of 
beef products for production, in some cases including beef brain and heart infusions, 
increasingly raises the spectre of BSE being transmitted through the vaccination of 
healthy herds. 
The most common medium for manufacturing clostridial vaccines is a basic 
concoction of boiled ground beef or liver combined with several salts.   While highly 
effective for promoting growth and toxin production of clostridial strains, there is a 
lack of consistency and reproducibility due to the nature of the product.  Lot to lot  
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Table 3: Standard Industrial Recipes for Clostridial Production 
 
  
  1943 1954 1962 1985 2007 
  
  
Chopped 
Meat 
Broth1 
Miller-
Muller2 Latham
3 
Reinforced 
Clostridial 
Broth4 
ISPAH Soy 
Media5  
    
Protein  
Ground Meat 500 g 0 g 0 g 0 g 0 g 
Beef Extract 0 g 0 g 0 g 10 g 0 g 
Casein Digest 30 g 22.5 g 25 g 0 g 0 g 
Tryptose 0 g 0 g 0 g 10 g 0 g 
Beef Heart Infusion 0 g 50 ml 0  0 g 0 g 
Soy Peptone 0 g 0 g 0 g 0 g 45 g 
Yeast Extract 5 g 0 g 0 g 3 g 0 g 
Sugar  Glucose 10 g 11 g 8 g 5 g 10 g 
Salts and 
Minerals 
NaCl 0 g 2.5 g 2.5 g 5 g 5 g 
Sodium Acetate 0 g 0 g 0 g 3 g 5 g 
Sodium Phosphate 0 g 2 g 0  0 g 0 g 
Potassium Phosphate 5 g 0.15 g 0  0 g 0 g 
Magnesium Sulfate 0 g 0.15 g 0.1 g 0 g 0 g 
Cysteine 0.5 g 0.25 g 0.125 g 0.5 g 0.5 g 
Tyrosine 0 g 0.5 g 0  0 g 0 g 
Calcium Pantothenate 0 g 1 mg 1 mg 0 g 0 g 
Uracil 0 g 2.5 mg 1.25 mg 0 g 0 g 
Nicotinic Acid 0 g 0  0.25 mg 0 g 0 g 
Thiamine 0 g 0.25 mg 0.25 mg 0 g 0 g 
Riboflavin 0 g 0.25 mg 0.25 mg 0 g 0 g 
Pyridoxine 0 g 0.25 mg 0.25 mg 0 g 0 g 
Biotin 0 g 2.5 µg 2.5 µg 0 g 0 g 
Vitamin B12 0 g 0  0.05 mg 0 g 0 g 
Iron  Reduced Iron Powder 0 g 0.5 g 0  0 g 0 g 
FeCl3 • 6H2O 0 g 0  32 mg 0 g 50 mg 
 
1 – (Mueller et al., 1943) 
2 –(Mueller & Miller, 1954) 
3 – (Latham et al., 1962) 
4 – (MacFaddin, 1985) 
5 – (Unpublished Research, Intervet-Schering Plough Animal Health) 
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variations in the meat, ranging from varying fat and protein levels to age and 
condition of the cattle from which the meat was rendered.  Added to that 
inconsistency is the increasing challenge of TSE diseases, as well as the potential for 
antigenic incompatibility with vaccinated animals results in a major challenge to the 
veterinary vaccine industry.  This remains the most commonly used medium for 
clostridial vaccine antigen production in the world. 
Several clostridial vaccines are made with a more defined medium based on 
the modified Mueller method , but even in these products significant residues of beef 
proteins, including the possibility of TSE infectious prions remain (Prusiner, 2004).  
And even these more defined media retain the potential for adverse anaphylactic 
reactions to non-host species proteins.   Because almost all animal food allergens 
have homologues in related species, these are far more likely to cause an 
anaphylactic reaction than an evolutionarily more distant species (Jenkins, 
Breiteneder, & Mills, 2007).  Anaphylactic reactions can range from minor site 
reactions, such as swelling and tenderness at the injection site, to systemic effects of 
fever, hemorrhaging, and even death.  While the percentage of vaccines made using 
this modified medium is growing, it still contains a very significant portion of 
animal-based components (peptones and caseins).   
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Manufacturing Methods for Clostridial Vaccines 
 
Because of the limited number of manufacturers in the United States, there is 
a limited repertoire of manufacturing methodologies and vaccine presentations 
available for clostridial vaccines.  A few are highly refined and comparable to the 
quality and consistency of human vaccine presentations of single-protein purified 
antigens.  But most are produced as a much cruder and cheaper product. 
The clostridial vaccines are produced by all veterinary vaccine manufacturers 
in nearly the same manner, with only minor modifications in media formulation and 
processing that are company/site specific.  The frozen seed stocks are subcultured 
into a volume of the standard medium, and passaged until a sufficient volume is 
generated to inoculate a large fermentor – typically 2500L or greater.  The fermentor 
is inoculated with the seed culture and monitored.  In some cases, additional sugars 
are added to enhance growth during the incubation.  After reaching the desired 
harvest criteria, the entire batch is inactivated with formaldehyde.  This kills the 
vegetative cells and any spores that are produced, as well as inactivating the 
toxigenic proteins to produce toxoids.  After a specified period of retention and 
testing, the bulk product is then processed.     
The simplest method for processing a bulk antigen into a vaccine presentation 
is simply to pass the whole culture across a low molecular weight tangential flow 
filtration unit in order to remove the majority of fluid volume while retaining all of 
the cells, debris and immunnogenic proteins in the retentate.  This whole-cell 
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concentrate is then supplemented with an adjuvant and excipients to increase 
stability and immunogenicity, followed directly by formulation into the final 
product. 
A slightly more refined method of processing involves using one of the 
available methods to remove the whole cells prior to low molecular weight tangential 
flow filtration to reduce the product volume.  While this procedure eliminates the 
large cells and majority of the debris, it still allows the majority all of the free 
proteins and nucleic acids to pass into the final concentrated product, including prion 
proteins.  Without extensive and expensive downstream processing like column 
chromatography or differential saltation precipitation, it is almost impossible to 
remove contaminating adventitious agents and prions from vaccine concentrates.     
Approximately half of all clostridial products have the cells and cell-debris 
removed prior to final processing by either continuous flow centrifugation or 
tangential flow filtration using micron-scale filters.  In all products, the final 
filtration step is processing over tangential flow membranes with a molecular cutoff 
of between 10kD and 50kD.  The final concentration step typically results in a 
reduction of volume of over 25-60 times (2500L reduced to between 40-100L).   
The concentrated bulk is mixed with other concentrated immunogens and excipients 
to make up the final dosed product.   While some vaccines are monovalent 
(containing a single immunogen), most for cattle, sheep and swine are polyvalent, 
containing up to 10 different immunogens.  This allows for a more cost effective and 
efficient means of vaccination for the farmer, but it also increases the overall 
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percentage per dose of concentrated beef products – and potentially prions and other 
unwanted contaminants.  While newer reformulations of some vaccines use as little 
as two milliliters in a dose for a 1000 pound cow, most vaccinations are between five 
and ten milliliters per dose.  Depending on the number of immunogens in the vaccine 
preparation, over 80% of that volume may be concentrated antigen (USDA-APHIS, 
2008b) and all of the residual material from the production medium and cell debris.    
In clostridial vaccine preparation, retaining the greatest percentage of 
immunogenicity in the final product is critical to ensure an efficacious dose in as 
small a volume as possible, while reducing the cost per dose.  Because the toxigenic 
proteins in most clostridial strains range from 60kD to 180kD, the most common 
processing filtration is done with 10kD nominal filters.   These provide efficient and 
effective concentration of the desired product, while allowing a rapid dewatering of 
the bulk to maximally reduce product volume.  Unfortunately, this also carries the 
potential for retention of other components and potentially antigenic fragments that 
are larger than the nominal size cutoff.   
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CHAPTER 3 - NEW RISKS IN OLD TECHNOLOGY 
 
The Start of a New Epidemic 
 
In 1986, several dozen cattle in Great Britain became ill with a new disease, 
and over the course of the following decade this evolved into a devastating epidemic 
that nearly wiped out the entire British beef and dairy cattle industry.  Bovine 
Spongiform Encepalopathy (BSE) would have been worrisome enough if it had 
restricted itself to just cattle.  But just a few years after the initial outbreak in cattle, 
several humans contracted a frighteningly similar disease called variant Creutzfeld-
Jacob Disease (vCJD) (Prusiner, 2004).   
These diseases are unusual.  The infectious agent wasn’t a virus, bacterium or 
fungus, and it didn’t even have nucleic acid.  The causative agent was a misfolded 
protein called PrP, which accumulated into amyloid plaques within the brain 
(McKinley, Bolton, & Prusiner, 1983).  These plaques caused lesions in the brain, 
eventually turning the normal brain into a spongy, debilitated mass of tissue.  The 
animals and people affected slowly lost motor, balance and cognitive function, which 
inevitably lead to death. 
Although this type of disease hadn’t been documented in cattle previously, a 
similar type of disease was well known to the sheep farmers – scrapie.  It was known 
that scrapie could be transmitted by feeding rendered animal carcasses to sheep, and 
the same transmissibility was shown to occur in both cattle and humans.  
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Prion proteins fall into the size range retained by the typical processing parameters of 
vaccine manufacturers.  The typical prion exists as a dimer of approximately 55kD 
(Prusiner, 2004).  In a typical batch production lot of vaccine made with chopped 
meat broth, over 15% of the final volume is concentrated beef broth and extract.  If a 
prion-infected carcass is used in the production of the antigen, then it is highly likely 
that the final bulk product will contain at least some measurable amount of prion 
protein. 
Although the meat and peptone products are fully autoclaved before 
inoculation, and the final culture harvest is inactivated with moderate concentrations 
of formaldehyde (0.5-1.0% vol/vol), there is still a concern over potential prion 
contamination.   Prions remain infectious in conditions that render nearly all other 
infectious particles and organisms inactive.  The protein amyloids can survive 
autoclaving at 132°C for over 240 minutes and exposure to formaldehyde 
concentrations up to 10% for over one hour (Giles et al., 2008).  The denaturing 
conditions necessary to render prions inactive would result in a complete loss of 
immunogenic activity in the clostridial antigens being processed.  And because 
prions form aggregate amyloids of random size distribution, filtration to eliminate 
the contamination is not effective (Prusiner, 2004). 
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Holes In The Defenses 
 
While the USDA has restricted the importation of bovine products from 
nations that have endemic BSE and screening and testing programs are in place at 
processing plants within the US, the testing is not 100% effective.  There have been 
numerous failures over the last several years in which BSE infected cattle have been 
imported and rendered at plants within the US.  As recently as 2006, BSE infected 
cattle have been identified by the USDA within USA feedstock and dairy livestock 
(USDA-APHIS, 2006).   
In 2004, 2005 and 2006, BSE infected cattle were discovered by the USDA 
screening and monitoring procedures.  In the 2004 case, the infected cattle were 
originally imported through Canada to the state of Washington.  In the subsequent 
investigation, the USDA was unable to account for all the index case’s cohort 
animals which were at high risk for infection.  Out of the 25 animals classified as 
“higher risk” of having BSE, only 14 were definitively identified and humanely 
culled, along with 230 other cattle in the suspect herds.  The index cow also had two 
offspring, which had been sold at auction to other operations.  After determining the 
identity and location of those two cattle, the entire herds were humanely euthanized - 
a total of 579 animals (USDA-APHIS, 2004).   In 2005, another identified case of 
BSE-infected cattle occurred in Texas.  Unlike in the 2004 Washington incident, the 
offspring of this cow could not be positively traced in all instances.  Because of the 
volume of cattle moving through the slaughter and processing system and the lack of 
 22 
identifiable records on the originating farm, several cohorts and offspring were 
unaccounted for even after extensive investigation (USDA-APHIS, 2005).  Less than 
a year later, another confirmed infection was identified in Alabama.  Like the Texas 
case, the lack of farm records hindered the tracing of all progeny and cohorts.  The 
herd of origin was never identified, nor were all of the offspring of the infected cow 
(USDA-APHIS, 2006). 
The European Union, one of the regions hardest hit by BSE infections, issued 
a report in 2004 (GBR, 2004) which determined that the current risk of BSE 
infectivity in the USA was “likely but not confirmed that domestic cattle are 
(clinically or pre-clinically) infected with BSE-agent.”  In their summary, the 
European Food Safety Authority determined that the risk to US cattle was not just 
from suspect imports arriving from at-risk nations, but also an internal threat due to 
the lack of an integrated, national animal identification system and a passive 
surveillance system, with only a small portion of active oversight in the highest “at-
risk” areas.  Based on the discovery of additional BSE infected cattle in the years 
following the European report, and the failure to trace all potential infective progeny 
and cohorts in those several cases demonstrates risk to US food safety, and the need 
to reduce any risk and challenge from BSE.   
There is little data available on the potential for iatrogenic transmission of 
prions through vaccination vectors.  Because of this dearth of empirical data, risks 
must be assessed through similar evaluations of other transmission means such as 
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blood and plasma transfusions in humans.  This is not ideal, however it is the only 
data available at present to compare risk of infections.   
From 2003 to 2007, there have been four documented cases of vCJD which 
were contracted from infected blood transfusion products (Turner & Ludlam, 2009).  
From the data presented, the risk for infection from transfusion is low, but still 
significant because there is no currently available screening test to detect prion 
proteins in the blood supply (Liras, 2008).  While human-human transmission 
through plasma and blood transfusions will most likely remain low due to increased 
scrutiny and monitoring of the donor blood supply, the risk of livestock infection 
from vaccinations containing high concentrations of bovine-derived components 
remains potentially significant.   
 For over 20 years, the only definitive confirmation for BSE infection has 
been a post-mortem dissection and examination of the brain for lesions and mis-
folded prion proteins.  Although several companies and research groups are actively 
working on an in-vitro live animal assay for prion infection, none have succeeded.  
Because there is no available test for prion proteins in live animals, it falls to the 
farmers and livestock processors to maintain vigilance and care in reporting suspect 
abnormal behavior in their animals.    
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Chapter 4 – ANIMAL-FREE COMPONENTS 
 
Plant Based Animal Free Components 
 
In the past, the availability of animal free media components was limited to a 
few plant based peptones or completely chemically-defined artificial media.  Within 
the last few decades, this limited repertoire has been enhanced with a great number 
of new manufacturers and products.  From the original soy-based plant peptones, 
there is now a tremendous diversity of products available, made from soy, potato, 
wheat, corn, pea, cottonseed and more.   
While these basal ingredients are considered “animal-free”, there is often 
some component of animal origin used during the processing and manufacture of the 
products.  Depending on the federal and/or international regulations that govern the 
labeling of media products, these additional animal-origin components may or may 
not be listed in the product literature.  Some of these additions are used in enzymatic 
treatments with extracts made from pancreatic and other organ lysates, to break 
down the protein and starch components into usable peptones and sugars.  These 
animal extracts are a minimal fraction of the total weight of the final product, but this 
can still affect the claim of “animal free” from the product.   
The alternative to using animal based enzymes to break down the proteins 
and starches is hydrolysis, which is effective but can be more expensive.  With 
increased pressure on manufacturers and a rising demand for 100% animal-free 
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products, these costs are steadily decreasing.   In 2009, Becton-Dickinson opened the 
world’s first fully animal-free component manufacturing facility in Miami, Florida 
(Biosciences, 2009).  This facility will allow the production of 100% animal-free 
components under the strictest FDA and EU manufacturing standards to ensure zero 
cross-contamination of products and defined traceability of all raw materials back to 
the tertiary level.  However, these new manufactured materials come with a high 
cost, which puts veterinary biological production at a distinct disadvantage.  While 
the prices of human pharmaceuticals and biologicals can rise much more readily with 
an increase in cost in raw materials, veterinary manufacturers are not so fortunate.  
Adding in the higher costs of raw materials will, at least in the short term, result in a 
lower return on investment per dose.  This, along with the increased costs associated 
with regulatory testing and validation of new processes, reduces the overall incentive 
for manufacturers to convert to a fully animal-free process. 
Animal free media have been used in the past to manufacture some clostridial 
species.  As early as 1971, it was shown that C. perfringens could be grown 
successfully in a medium containing soy proteins (Busta & Schroder, 1971).  In the 
last decade, there has been an emphasis in the human biological pharmaceutical 
industry to use soy-based media for manufacturing C. tetani and C. botulinum.  
Because tetanus toxoid is a highly purified and concentrated antigen that is 
administered to humans, there is a much greater awareness and concern with 
potential contaminates like BSE.  In 2007, a paper by Fang et al. outlined a soy-
based medium that was successfully used to manufacture tetanus toxoid (Demain, 
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George, Kole, Gerson, & Fang, 2007).  Based on these studies, it is clear that 
clostridial strains can be readily grown in media free from animal products. 
In 2007, researchers at Intervet-Schering Plough Animal Health (ISPAH) 
developed a non-animal based medium formula using a soy peptone base which 
allowed strong growth and toxin production in several clostridial strains.  This new 
medium formulation eliminates all sources of animal derived components, however 
it is not in full production for all clostridial vaccine strains.  Continued efforts have 
been made in the last two years to improve the media and modify the formula to 
enhance growth and toxin production of all commercial vaccine strains.   
Over the decades, from the first clostridial vaccine manufacturing processes 
of the 1940’s up through today, there has been a minor effort to reduce the 
percentage of animal-based products in the production media.  From the original 
chopped meat broths, which were composed of nearly 100% animal products, 
through the 1960’s and up to the 1990’s with modified component media slowly 
upgraded and improved, there has remained a reliance on animal based components.  
It has only been in the last few years that the practical, full-scale production of 
completely animal-free media has been emphasized.  (Figure 1)  These animal-free 
products only represent a few percent of the total vaccine production worldwide, 
with the vast majority still produced using animal-based components, with nearly 
half of those products made in CMB, the medium most at risk for transmitting BSE 
(Constance, 2009). 
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Figure 1: Reduction of Animal-Based Components in Clostridial Media 
1943 1954 1962 1984 2007
CMB MM Latham RCM ISPAH Soy
Animal Based Animal Free Sugars, Minerals & Vitamins
CMB – (Mueller, Schoenbach, Jezukawicz, & Miller, 1943), MM –(Mueller & Miller, 1954), Latham – (Latham, Bent, & 
Levine, 1962), RCM – (MacFaddin, 1985), ISPAH Soy – (Unpublished Research, Intervet-Schering Plough Animal 
Health) 
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Advantages and Benefits of Switching To Animal-Free Media 
 
 The most obvious benefit in converting to an animal-free media base for 
clostridial vaccine production is the immediate end to any risk of prion-transmissible 
disease.  With no animal source in any of the products, the risk of post-vaccination 
infection, and the potential for subsequent introduction into the human food supply, 
is eliminated.   
When animal-based products are used in the manufacture of a vaccine, the 
possibility exists for an anaphylactic reaction to antigenic peptides that remain in the 
preparation from the source animal (Ellenberg, 2001).  In the case of cattle receiving 
an injection made from bovine products, this is not a major concern.  But in the case 
of sheep, poultry or swine, these bovine antigenic peptides can result in significant 
losses of market weight (Cooper & Jull, 1966).  These reactions can range from large 
and painful site reactions to death.  The site reactions result in damage to the 
animal’s meat, which must be removed prior to processing (Stokka, Edwards, Spire, 
Brandt, & Smith, 1994).  This can cause a loss of several pounds of meat, and a 
concomitant loss of revenue for the farmer.  In extreme cases, the reaction has been 
strong enough to sicken the animals enough to reduce final weight by 10-20%, which 
represents a significant financial loss.  In rare cases, there is enough of an 
anaphylactic reaction to kill the animal, resulting in a 100% loss of investment.  One 
significant advantage of using plant-based media is that there is a far smaller 
incidence of immunogenic anaphylactic reaction in the receiving animal, so the 
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damage and loss is reduced considerably (Jenkins et al., 2007; Wells, Pass, & Eyre, 
1974).   
 Although there is a significant up-front cost associated with moving 
production to animal-free media due to testing, evaluation and regulatory compliance 
issues, the long term benefits are tremendous.  Not only is the cost of the raw 
materials often significantly lower, but the labor, equipment and facility expenses are 
also reduced less.  In addition, there is the potential to more fully optimize the 
formulation of media that, in many cases, have not been altered for several decades.  
This opportunity provides the potential to significantly increase the yield per liter of 
unconcentrated bulk antigen, which will further save on costs and animal facility 
capacity per year 
 
Challenges Associated with a Transition to Animal-Free 
 
One of the risks to companies when making a switch of the media used in a product 
is the costs and regulatory restrictions imposed by the governing agency that 
oversees the safety and efficacy of the products.  These costs can vary from hundreds 
of thousands to tens of millions of dollars, depending on the extent of change and 
level of restrictions and testing imposed by the governing agencies (Constance, 
2009).  Because of these costs, there has been little incentive over the last half-
century to change product lines that have reliably produced efficacious products at a 
reasonable expense.  Unfortunately for those companies, the regulatory climate and 
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scientific reality has presented a situation where continuing to use a century-old 
manufacturing process is no longer feasible.  Current clostridial vaccines are very 
inexpensive for the consumer to purchase.  This restricts the manufacturer’s return 
on investment to only a fraction of a cent per dose.  In 2007, the cost to vaccinate a 
100 head herd of cattle with a 7-way clostridial vaccine cost less than $25.00 
(USDA-APHIS, 2008a).    
Animal-free media have been available for many years, but have not been 
used in the manufacture of veterinary clostridial vaccines for a variety of reasons.  
Because of the limited revenue that clostridial vaccines provide for the companies, 
there is a limited budget or interest in altering the product lines if substantial costs 
are required.  The most significant cost arises from regulatory requirements and 
optimization challenges.  While it is a fact that in most cases, prepared vegetable-
based powdered media are equal to or less costly than equivalent peptone or cooked-
meat media, this is only a nominal portion of the costs that such a switch would 
demand.  However, there is the need for research to identify an optimal medium 
composition that not only provides a good basal growth medium, but also has the 
appropriate conditions for antigen production – the expression of toxins and 
immunogenic cellular components.  The ideal medium formulation will maximize 
not only the overall cell mass produced, but also the toxin produced per cell.   
Unfortunately, very little is known about the expression requirements and 
timing for nearly all of the clostridial toxins.  While it is known that a few of the 
toxins are expressed during sporulation, many are expressed during other growth 
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phases or are triggered by unidentified environmental stimuli.  Additionally, there 
are no cost-effective and reliable in vitro tests for potency and efficacy, so nearly 
every clostridial antigen must be evaluated by expensive, restrictive and time 
consuming animal testing.  These additional costs add to an already strained budget, 
and reduce the corporate incentive to voluntarily take on the challenges involved in 
switching to animal-free media.  Along with the significant scientific challenges and 
financial costs described here, there are also the potentially significant challenges 
posed by regulatory bodies, such as additional media prion-testing requirements, 
reduced availability of prion-free stock herds, and expensive final product testing for 
prion contamination.   
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CHAPTER 5 – CONCLUSION 
 
Discussion 
 
 Vaccination of cattle against the clostridials has been one of the most 
successful and cost effective means of ensuring a safe and reliable food supply in the 
history of modern agriculture.  However, the challenges of the new and emerging 
threats posed by prions have set the stage for a change in how we think about the 
production of clostridial vaccines.   While traditional meat- and animal-based media 
have held strong in veterinary vaccine production for most of the past century, the 
increasing availability and gradually falling cost of animal-free replacement media is 
slowly pushing the industry to a new standard.   
 The regulatory agencies that oversee the manufacturers worldwide have 
pushed hard on the human biologicals and pharmaceutical industries to remove all 
animal-based products and components from their manufacturing processes.  It is 
only a matter of time before the same pressures are exerted on the veterinary 
industry.  While it will be costly for vaccine manufacturers to change over to a new 
process, as well as to the end users who will have to pay for the additional costs 
through price increases, the cost of losing a vaccine product from the market because 
of changing regulations is much greater.  Further, any additional costs and expenses 
incurred through these modifications will ultimately be passed on through the market 
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to the food producers, and ultimately onto the end consumer as higher prices at the 
grocery stores. 
 
Recommendations for the Future 
 
 The veterinary vaccine industry is small relative to the overall biotechnology 
sector, but its impact on the health and safety of the food industry is tremendous.  By 
moving quickly to a substantially animal-free manufacturing process for all 
clostridial antigens, there will be an even greater emphasis on food safety and the 
prevention of new outbreaks of frighteningly devastating disease. 
 Several veterinary vaccine manufacturers are already starting to experiment 
with a change to completely animal-free, plant-based media for production of 
clostridial vaccines.  However, even those manufacturers have not yet succeeded in 
completely eliminating animal-based components from all of their clostridial product 
lines.  The use of animal-based components will continue to grow as a significant 
threat to the human food supply, due to risks ranging from anaphylactic reactions to 
TSE transmissibility. 
 The regulatory agencies which provide oversight to the veterinary vaccine 
industry are under pressure to push new incentives and regulations on manufacturers 
so that complete incorporation of animal-free production can be rapidly and 
effectively introduced into all clostridial vaccine products.  All of the vaccine 
manufacturers in the United States also export some of their products overseas, 
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meaning that the same products are licensed under multiple international regulatory 
agencies.  The often contradictory and duplicative restrictions imposed by these 
agencies to altering vaccine production methods and formulations results in an 
industry-wide stagnation and unwillingness to change the status quo.   
 Using innovations developed from human pharmaceutical manufacturing 
processes in removing animal based components from their products, as well as the 
very recent developments of animal-free media for production of at least some of the 
clostridial vaccine strains, the risk of BSE-related infection from vaccination will 
rapidly be eliminated.   
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